Mr. David L. Hallal is Co-Founder of ElevateBio, LLC and has been its Executive Chairman since April 2025. He served as Chairman and Chief Executive Officer of ElevateBio LLC until April 2025. He is CEO of...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
David Hallal	CEO & Chairman of the Board	no data	US$400.85k	0.31% $ 8.7m
Mo Qatanani	Chief Scientific Officer	1.3yrs	US$2.96m	0.021% $ 604.6k
Akshay Vaishnaw	President of R&D	less than a year	US$281.26k	0.010% $ 282.2k
Jing Marantz	Chief Medical Officer	2.5yrs	US$3.08m	0.013% $ 374.8k
Vikas Sinha	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Robert Woods	Chief Operating Officer	less than a year	geen gegevens	geen gegevens
Erin Moore	Interim Principal Financial & Accounting Officer	5.6yrs	geen gegevens	0.087% $ 2.5m
Rushmie Nofsinger	Vice President of Corporate Affairs & Investor Relations	no data	geen gegevens	geen gegevens
Junlin Ho	General Counsel & Corporate Secretary	5.2yrs	US$2.13m	0.10% $ 2.9m
Caryn Parlavecchio	Chief Human Resources Officer	3.8yrs	geen gegevens	0.062% $ 1.7m
Edward Myles	Senior Advisor	less than a year	US$2.01m	0% $ 0
Lisa Price	Senior Vice President of Human Resources	no data	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SRRK wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Hallal	CEO & Chairman of the Board	7.8yrs	US$400.85k	0.31% $ 8.7m
Akshay Vaishnaw	President of R&D	11.3yrs	US$281.26k	0.010% $ 282.2k
Michael Gilman	Independent Director & Member of Scientific Advisory Board	11.5yrs	US$283.35k	0.054% $ 1.5m
Timothy Springer	Member of Scientific Advisory Board	no data	US$48.97k	geen gegevens
Jeffrey Flier	Independent Director & Member of Scientific Advisory Board	8.6yrs	US$288.76k	0.047% $ 1.3m
Leonard Zon	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Daniel Rifkin	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Kristina Burow	Independent Director	10.8yrs	US$282.94k	0.020% $ 562.1k
Joan Massague	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Scott L. Friedman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Barry Coller	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Joshua Reed	Independent Director	4.2yrs	US$288.76k	0.014% $ 402.9k

9.7yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SRRK wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.7 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/05/30 02:20
Aandelenkoers aan het einde van de dag	2025/05/30 00:00
Inkomsten	2025/03/31
Jaarlijkse inkomsten	2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Scholar Rock Holding Corporation wordt gevolgd door 16 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Madhu Kumar	Baird
Etzer Darout	BMO Capital Markets Equity Research
Guyn Kim	BMO Capital Markets Equity Research

Scholar Rock Holding Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Board Member notifies of intention to sell stock

Insufficient new directors

Scholar Rock Appoints Vikas Sinha as Chief Financial Officer

Chief Commercial Officer notifies of intention to sell stock

Scholar Rock Holding Corporation, Annual General Meeting, May 22, 2025

Scholar Rock Holding Corporation Announces Executive Changes

Recent updates

Board Member notifies of intention to sell stock

Consensus revenue estimates fall by 73%

No longer forecast to breakeven

New minor risk - Profitability

Insufficient new directors

Scholar Rock Appoints Vikas Sinha as Chief Financial Officer

Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade

Chief Commercial Officer notifies of intention to sell stock

FDA Grants Priority Review for Biologics License Application (BLA) and Ema Accepts Marketing Authorisation Application (MAA) for Apitegromab as A Treatment for Spinal Muscular Atrophy

Scholar Rock Holding Corporation, Annual General Meeting, May 22, 2025

Scholar Rock Holding Corporation Announces Executive Changes

Scholar Rock Holding Corporation Announces Executive Changes

Senior Advisor exercised options and sold US$2.5m worth of stock

Forecast to breakeven in 2027

New major risk - Shareholder dilution

President recently sold US$677k worth of stock

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data

Scholar Rock Announces the Appointment of Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

President recently sold US$986k worth of stock

Scholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, But Price Too High

Price target increased by 15% to US$42.88

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million.

Price target increased by 11% to US$29.75

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

New major risk - Financial position

Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

CFO, COO & Treasurer recently sold US$85k worth of stock

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

Price target increased by 8.1% to US$26.25

New minor risk - Share price stability

New major risk - Financial position

President recently sold US$183k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Scholar Rock: Solid Data And Good Prospects

CFO, COO & Treasurer notifies of intention to sell stock

Senior VP & Head of Research recently sold US$295k worth of stock

CFO, COO & Treasurer notifies of intention to sell stock

Price target increased by 7.1% to US$25.71

New major risk - Revenue and earnings growth

CFO, COO & Treasurer notifies of intention to sell stock

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Price target increased by 9.8% to US$24.00

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Price target decreased to US$22.57

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Jay Backstrom is the new CEO at Scholar Rock

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Price target decreased to US$29.00

Consensus revenue estimates increase by 75%